Therapeutic Area | MeSH |
---|---|
neoplasms | D009369 |
hemic and lymphatic diseases | D006425 |
immune system diseases | D007154 |
Brand Name | Status | Last Update |
---|---|---|
clofarabine | ANDA | 2024-02-27 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
lymphoid leukemia | — | D007945 | C91 |
Code | Description |
---|---|
J9027 | Injection, clofarabine, 1 mg |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Myeloid leukemia acute | D015470 | — | C92.0 | 14 | 21 | 3 | — | — | 33 |
Leukemia | D007938 | — | C95 | 13 | 17 | 1 | — | — | 25 |
Myelodysplastic syndromes | D009190 | — | D46 | 10 | 15 | 1 | — | — | 22 |
Graft vs host disease | D006086 | — | D89.81 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 11 | 8 | — | — | — | 15 |
Myeloid leukemia | D007951 | — | C92 | 3 | 7 | — | — | — | 8 |
Neoplasms | D009369 | — | C80 | 7 | 2 | — | — | — | 7 |
Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 3 | 2 | — | — | — | 4 |
Preleukemia | D011289 | — | — | 1 | 3 | — | — | — | 4 |
Non-hodgkin lymphoma | D008228 | — | C85.9 | 4 | 2 | — | — | — | 4 |
B-cell chronic lymphocytic leukemia | D015451 | — | C91.1 | 4 | 1 | — | — | — | 4 |
Lymphoid leukemia | D007945 | — | C91 | 3 | 2 | — | — | — | 4 |
Recurrence | D012008 | — | — | 2 | 2 | — | — | — | 4 |
Syndrome | D013577 | — | — | — | 3 | — | — | — | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hematologic neoplasms | D019337 | — | — | 2 | — | — | — | — | 2 |
Myeloproliferative disorders | D009196 | — | D47.1 | 1 | — | — | — | — | 1 |
Primary myelofibrosis | D055728 | — | D47.4 | 1 | — | — | — | — | 1 |
Promyelocytic leukemia acute | D015473 | — | C92.4 | 1 | — | — | — | — | 1 |
Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
Acute disease | D000208 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Clofarabine |
INN | clofarabine |
Description | Clofarabine is a purine nucleoside analogue consisting of a 6-amino-2-chloropurin-9-yl group attached to the 1beta position of 2'-deoxy-2'-fluoro-D-arabinofuranose. It is metabolized intracellularly to the active 5'-triphosphate metabolite, which inhibits DNA synthesisis and so stops the growth of cancer cells. Clofarabine is used as an antimetabolite antineoplastic agent in the treatment of relapsed or refractory acute lymphoblastic leukaemia. It has a role as an antineoplastic agent and an antimetabolite. It is an organofluorine compound and a member of adenosines. |
Classification | Small molecule |
Drug class | antineoplastics (arabinofuranosyl derivatives) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Nc1nc(Cl)nc2c1ncn2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F |
PDB | — |
CAS-ID | 123318-82-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1750 |
ChEBI ID | 681569 |
PubChem CID | 119182 |
DrugBank | DB00631 |
UNII ID | 762RDY0Y2H (ChemIDplus, GSRS) |